HKBU Develops Chinese Medicine for Ulcerative Colitis
The Centre for Chinese Herbal Medicine Drug Development (CDD) at Hong Kong Baptist University (HKBU) has achieved a remarkable milestone in the treatment of ulcerative colitis. The team's recent breakthrough involves a new Chinese herbal formulation designed to help maintain remission for patients facing this challenging condition. Following the submission of an Investigational New Drug application for CDD-2103 to the National Medical Products Administration (NMPA), the centre proudly announced its approval to initiate clinical trials.
Clinical Trial Authorization Marks a Milestone
Recently, the NMPA granted approval, paving the way for a Phase II clinical trial scheduled for next year. This trial will evaluate the safety and effectiveness of CDD-2103. This groundbreaking step not only opens up possibilities for more effective treatments but also highlights the centre's dedication to integrating traditional practices with modern medical advancements.
Understanding Ulcerative Colitis and Its Challenges
Ulcerative colitis is a form of inflammatory bowel disease that is increasingly common, particularly in areas where traditional diets may not support gut health. Patients often endure debilitating symptoms, including diarrhea, rectal bleeding, and severe abdominal cramps, which can greatly diminish their quality of life.
Managing ulcerative colitis is complex, as it is categorized into active and remission phases. Current treatment options frequently fall short, struggling to maintain remission or prevent relapses effectively. Motivated by the need for improved solutions, researchers at HKBU have developed CDD-2103, which combines various traditional Chinese herbal medicines, such as Codonopsis Radix and Curcumae Longae Rhizoma. This formulation is designed to target specific symptoms related to spleen deficiency and the accumulation of internal damp heat.
Research and Development of CDD-2103
A clinical trial conducted by the research team indicated that CDD-2103, when administered as a decoction, was well-tolerated by patients without any adverse effects. The team has since advanced to develop CDD-2103 in granule form, adhering to the rigorous quality control standards set by the NMPA, and has completed essential preclinical studies.
Promising findings revealed that CDD-2103 effectively inhibited the progression of colitis by fostering a tolerogenic immune microenvironment. It does this by modulating the differentiation of regulatory T-cells and reducing the presence of inflammatory macrophages in the colon, contributing to a healthier gut barrier. These studies have been documented in respected journals, including the Journal of Advanced Research and the Journal of Ethnopharmacology.
Future Prospects and Expectations
Professor Bian Zhaoxiang, a key figure in this initiative, expressed hope about the potential of this development to enhance patients' quality of life. He pointed out that CDD-2103 represents a fusion of modified ancient formulations and contemporary scientific methods. The approval for a Phase II clinical trial signifies a significant acknowledgment of the research team's hard work and commitment.
Focus on Safety and Efficacy
The upcoming randomized, double-blind, placebo-controlled trial in Mainland China will specifically assess the safety and efficacy of CDD-2103 in patients who are in remission. Dr. Tan Hor Yue, an assistant professor at CDD, noted that larger-scale trials anticipated in the coming years will provide crucial validation of CDD-2103's therapeutic effects.
The Role of CDD in Innovation
Situated within the Hong Kong Science Park, CDD is a unique centre dedicated exclusively to the research and development of Chinese herbal medicines at a local university. Since its establishment in 2020, CDD has focused on pioneering research aimed at addressing gastrointestinal and immune-related diseases, managing chronic constipation, and specifically targeting ulcerative colitis. This work is supported by funding from the Innovation and Technology Commission's InnoHK initiative.
Frequently Asked Questions
What is CDD-2103?
CDD-2103 is a novel Chinese herbal formulation developed to help maintain remission in patients with ulcerative colitis.
Where has the clinical trial for CDD-2103 been approved?
The clinical trial has received approval from the National Medical Products Administration (NMPA).
What symptoms does ulcerative colitis cause?
Common symptoms include diarrhea, rectal bleeding, and abdominal cramps, all of which severely affect patients' quality of life.
How does CDD-2103 work?
CDD-2103 functions by modulating the immune system to enhance gut health and reduce inflammation in the colon.
What makes CDD unique?
CDD is the only centre within a local university that focuses specifically on the development of Chinese herbal medicines, innovating for gastrointestinal and immune-related diseases.
